First-Line Treatment of Advanced Renal Cell Carcinoma with Temsirolimus
|
|
- Dustin Jennings
- 6 years ago
- Views:
Transcription
1
2 Modified Practice Guideline: Systemic Therapy Summary First-Line Treatment of Advanced Renal Cell Carcinoma with Temsirolimus (GENU-Temsirolimus) Effective: January 2009 Required Update: February 2014 Annual Review: February 2013 CCMB Electronic Posting Date:
3 Systemic Therapy Summary 2 ACKNOWLEDGEMENT AND SPONSORSHIP DISCLAIMERS Effective: May 2012 Required Update: February 2014 Annual Review: February 2013 Approved: Ferbuary 2013 p. 2
4 Systemic Therapy Summary 3 Introduction This document has been prepared by the Winnipeg Regional Health Authority/CancerCare Manitoba (WRHA/CCMB) Oncology Pharmacotherapeutic (P&T) Subcommittee s Systemic Therapy Summaries Working Group, as a means of disseminating drug information and formulary decisions made by the Subcommittee. The CCMB Provincial Pharmacy Program, Provincial Oncology Drug Program (PODP), and Clinical Practice Guidelines Initiative (CPGI) have contributed to the development of this summary. Systemic Therapy Summaries (STS) are being developed for drugs/or indications where clinical benefit has been accepted by the P&T Subcommittee, based on scientific data. All STS documents are approved by the P&T Subcommittee Chair and the CPGI Lead/Advisory Panel Chair. The content of this STS was in large part adapted from the Formulary Addition Request submitted to the P&T Subcommittee by the CCMB Gastro Intestinal (GI) Disease Site Group, May, This document will be reviewed, and updated as necessary, once in every twelve month period; unless emerging evidence from scientific research dictates otherwise. Purpose This document is intended as a guide to facilitate the safe and effective clinical use of temsirolimus in the firstline treatment of advanced renal cell carcinoma. For this purpose, it may be used by qualified and licensed healthcare practitioners involved with the care of oncology patients, which may include (but is not limited to): physicians, nurses, and pharmacists at CancerCare Manitoba, Community Cancer Programs Network (CCPN) sites, and WRHA Community Oncology Program sites. Disclaimer Use of this document should not preclude the practitioner s independent clinical judgment, nor should it replace consultation with the oncologist. It is the responsibility of the practitioner to develop an individualized treatment plan for each patient under his/her care, and ideally this should take place within the context of a multidisciplinary team. The unique needs and preferences of the patient and the family should always be reflected in the plan of care. This document is not a comprehensive drug monograph. Practitioners must refer to other sources for complete drug information. Effective: May 2012 Required Update: February 2014 Annual Review: February 2013 Approved: Ferbuary 2013 p. 3
5 Systemic Therapy Summary 4 First-Line Treatment of Advanced Renal Cell Carcinoma with Temsirolimus Protocol Code: GENU-Temsirolimus Developed by: Genitourinary (GENU) Systemic Therapy Group Date of Presentation to P&T Subcommittee: January 2009 Treatment Recommendation Temsirolimus is an option for the first line treatment of advanced renal cell carcinoma for patients who meet the inclusion criteria stated below. Treatment Intent Non curative Prolongation of overall survival and progression free survival Rationale Most cases of metastatic renal cell carcinoma cannot be cured. Interferon alfa and interleukin 2 have been the main treatments for metastatic renal cell carcinoma. These cytokines have limited efficacy, substantial toxicity, and minimal benefit in patients with extensive tumor burden and adverse prognostic factors. Temsirolimus, an mtor (mammalian target of rapamycin) inhibitor, has demonstrated a survival advantage in this high risk patient population. Clinical Benefit (Level 1 Evidence see Appendix I) Support for the use of temsirolimus in newly diagnosed advanced renal cell carcinoma comes from the Phase III Global Advanced Renal Cell Carcinoma (ARCC) trial (Hudes G, et al. 2007). The trial compared three arms of treatment in a patient population with poor prognosis disease (n= 626): temsirolimus alone, temsirolimus and interferon alfa, and interferon alfa alone. Eligibility criteria were restricted to patients with at least three of the following six predictors of short survival: a corrected serum calcium level of more than 2.5 mmol/l; a time from initial diagnosis to randomization of less than 1 year; a Karnofsky performance status score of 60 or 70; metastases in multiple organs; a serum lactate dehydrogenase (LDH) level of more than 1.5 times the upper limit Effective: May 2012 Required Update: February 2014 Annual Review: February 2013 Approved: Ferbuary 2013 p. 4
6 Systemic Therapy Summary 5 of the normal range; a hemoglobin level below the lower limit of the normal range. The primary endpoint of the study was overall survival. Patients who received temsirolimus alone had a longer median overall survival than interferon alone (10.9 months vs. 7.3 months; statistically significant). Progression free survival was also longer in the temsirolimus alone arm. The study results showed that the combination of temsirolimus and interferon did not improve survival. Patient Population and Selection Criteria Inclusion criteria (January 2009) This treatment may be offered to patients with advanced or metastatic renal cell carcinoma (both clear cell and non clear cell histology) with poor prognosis, defined as having at least 3 of the following 6 criteria (Hudes G, et al 2007): Serum LDH of more than 1.5 times the upper limit of normal range Corrected serum calcium level above the upper limit of normal range (greater than 2.6 mmol/l) Time from initial diagnosis of renal cell carcinoma to treatment of less than 1 year ECOG performance status score of 2 or lower (see Appendix II) Metastases in multiple organs Hemoglobin level below the lower limit of normal range Exclusion criteria (January 2009) Major surgery within the last 4 weeks Active brain metastases Fasting cholesterol level greater than 9.1 mmol/l Fasting triglyceride level greater than 4.5 mmol/l ECOG performance status 3 or greater Effective: May 2012 Required Update: February 2014 Annual Review: February 2013 Approved: Ferbuary 2013 p. 5
7 Systemic Therapy Summary 6 CCMB Formulary Status 1. Formulary definition Non Formulary* P&T Subcommittee Drug Approval Process Step 2a** * Case by case approval by the P&T Subcommittee Chair is required. A Non Formulary Drug Request Form must be completed. ** Clinical benefit accepted by the P&T Subcommittee based on scientific evidence. Cost effectiveness analysis demonstrates a potentially unacceptable cost effectiveness and/or budget impact. 2. Adjudication process Request form to use: Non Formulary Request Form 2008 update (J:\Forms\Pharmacy) Approval required by: P&T Subcommittee Chair 3. Restrictions Prescribing of temsirolimus should be first approved by the Genitourinary (GENU) Systemic Therapy Group. Effective: May 2012 Required Update: February 2014 Annual Review: February 2013 Approved: Ferbuary 2013 p. 6
8 Systemic Therapy Summary 7 Treatment Regimen GENU Temsirolimus 1 cycle = 4 weeks (planned treatment 6 cycles) Drug Dose CCMB Administrative Guideline Temsirolimus 25 mg once weekly IV in 250mL NS (non PVC bag) over 30 to 60 minutes (use non PVC tubing with in line filter) Supportive Care Medications Drug Dose CCMB Administrative Guideline Effective: May 2012 Required Update: February 2014 Annual Review: February 2013 Approved: Ferbuary 2013 p. 7
9 Systemic Therapy Summary 8 Clinical Monitoring and Follow-Up Recommendations Hematology and chemistry laboratory tests Before each dose: CBC (including platelets) At baseline and prior to each 4 week cycle: CBC, platelets, electrolytes, creatinine, BUN, serum glucose, calcium, phosphorus, AST, LDH, total bilirubin, alkaline phosphatase, total cholesterol, triglycerides Clinical toxicity assessment (Use CTCAE v.4.0, see Appendix III) Prior to each cycle: assess patient for signs and symptoms of hyperglycemia, bleeding, fluid retention, skin toxicity, infections, nausea & vomiting, mucositis, diarrhea Assessment of treatment response Clinical follow up with diagnostic imaging every 2 months. Treatment should continue until the patient is no longer benefiting clinically from therapy or unacceptable toxicity occurs. Common or Clinically Important Adverse Events* (Refer to individual drug monographs for full details of adverse events) Hyperglycemia Hyperglycemia was reported on at least one occasion, in over 82% of patients receiving temsirolimus. Approximately 16% of patients have a serum glucose level of greater than 13.9 mmol/l reported on one occasion. Hyperglycemia may necessitate dose modification and treatment with insulin. Hyperlipidemia Hypercholesterolemia and/or hypertriglyceridemia (total cholesterol greater than mmol/l and/or triglycerides greater than 5 times upper limit of normal) were present in approximately 45% of patients. Hematological toxicity Grade 3 or 4 anemia was reported in 20% of patients receiving temsirolimus weekly. Grade 3 or 4 leukopenia, neutropenia, and thrombocytopenia occurred in 1%, 5%, and 1% of patients respectively. Bleeding Bleeding events were observed in 25% of patients who received temsirolimus. The most common bleeding event was epistaxis (12% of patients). Most bleeding events were grade 1 or 2 and only 3% were grade 3 or 4. Other adverse effects Edema/peripheral (28%, severe 3%) Hematuria (31%, severe 1%) Proteinuria (36%, severe less than 1%) * See Appendix III CTCAE v.4.0 Effective: May 2012 Required Update: February 2014 Annual Review: February 2013 Approved: Ferbuary 2013 p. 8
10 Systemic Therapy Summary 9 Precautions Respiratory Cases of interstitial lung disease have occurred in patients who received temsirolimus. Patients should be followed closely for clinical respiratory symptoms. Caution is advised for the use of this drug in patients with significant lung dysfunction. Hypersensitivity reactions Hypersensitivity reactions, including anaphylactic reactions, have occurred with the administration of temsirolimus. Most reactions have occurred with initial dosing. Infections Temsirolimus may be immunosuppressive. Patients should be observed for Effective: May 2012 Required Update: February 2014 Annual Review: February 2013 Approved: Ferbuary 2013 p. 9
11 Systemic Therapy Summary 10 Dose Modifications Hepatic dysfunction Temsirolimus is mainly metabolized and excreted through the liver. Caution should be exercised and dose modifications considered in patients with moderate to severe hepatic impairment. Renal dysfunction A very small percentage of temsirolimus and its metabolites are excreted by the kidney. No data exist for temsirolimus in patients with moderate to severe kidney failure. Hematological toxicity Day 1 Blood Counts ANC greater than or equal to 1.0 x 10 9 /L and Platelets greater than or equal to 75 x 10 9 /L Dose 100% ANC less than 1.0 x 10 9 /L or Platelets less than 75 x 10 9 /L Hold until ANC greater than or equal to 1.0 x 10 9 /L and Platelets greater than or equal to 75 x 10 9 /L Reduce by 5 mg/week Non Hematological toxicity Grade of Temsirolimus related adverse events Grade % Dose Adjustments Intolerable Grade 2 Reduce by 5 mg/week Grade 3 or 4 Hold until recovered to grade 2 or lower AND Effective: May 2012 Required Update: February 2014 Annual Review: February 2013 Approved: Ferbuary 2013 p. 10
12 Systemic Therapy Summary 11 Drug Interactions Temsirolimus is metabolized primarily by cytochrome P450 3A4. Potential drug interactions with inducers or inhibitors must be considered. CYP3A4 inducers may decrease exposure of temsirolimus and its metabolite, sirolimus. CYP3A4 inhibitors may increase blood concentrations of temsirolimus and sirolimus. Temsirolimus in combination with sunitinib, gemcitabine or fluorouracil has been associated with serious adverse drug reactions. Fatal events have been seen when temsirolimus was combined with fluorouracil. Effective: May 2012 Required Update: February 2014 Annual Review: February 2013 Approved: Ferbuary 2013 p. 11
13 Systemic Therapy Summary 12 References 1. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, Interferon Alfa, or Both for Advanced Renal Cell Carcinoma. The New England Journal of Medicine. 356; 22 (May 31, 2007): Torisel (Temsirolimus) product monograph. Wyeth Canada. 19 July 2007 edition. Ministry of Health and Long Term Care. Government of Ontario. Joint Oncology Drug Review and CED Recommendations. 3. BCCA Cancer Agency. BCCA Protocol Summary for Therapy for Advanced Renal Cancer Using Temsirolimus. Accessed from website January 31, CancerCare Ontario. CCO Regimen Code: Temsirolimus and CCO Drug Monograph for Temirolimus. Accessed from website January 31, Effective: May 2012 Required Update: February 2014 Annual Review: February 2013 Approved: Ferbuary 2013 p. 12
14 Systemic Therapy Summary 13 CCMB Contributors Dr. Piotr Czaykowski, Medical Oncologist, Genitourinary Systemic Therapy Group Mr. Marc Geirnaert, BSc (Pharm), Genitourinary Systemic Therapy Group Ms. Kimberly Watkinson, BSc (Pharm), Provincial Oncology Drug Program Ms. Kristi Hofer, BSc (Pharm), Community Cancer Programs Network Contact Physician Dr. Piotr Czaykowski, Medical Oncologist, Genitourinary Systemic Therapy Group Approved By Dr. Sri Navaratnam, Medical Oncologist Chair, WRHA/CCMB Oncology Pharmacotherapeutic Subcommittee Dr. Piotr Czaykowski, Medical Oncologist Lead and Advisory Panel Chair, CCMB Clinical Practice Guidelines Initiative We gratefully acknowledge the support of CancerCare Manitoba, and the CancerCare Manitoba Foundation. The Provincial Oncology Clinical Practice Guidelines Initiative Effective: May 2012 Required Update: February 2014 Annual Review: February 2013 Approved: Ferbuary 2013 p. 13
15 Systemic Therapy Summary 14 Appendix I Levels of Evidence Ia Evidence obtained from meta analysis of randomised controlled trials Ib Evidence obtained from at least one randomised controlled trial IIa Evidence obtained from at least one well designed controlled study without randomisation IIb Evidence obtained from at least one other type of well designed, quasi experimental study III Evidence obtained from well designed, non experimental descriptive studies, such as comparative studies, correlation studies and case studies IV Evidence obtained from expert committee reports or opinions and/or clinical experience of respected authorities British Committee for Standards in Haematology Effective: May 2012 Required Update: February 2014 Annual Review: February 2013 Approved: Ferbuary 2013 p. 14
16 Systemic Therapy Summary 15 Appendix II ECOG Performance Status Scale 0 Fully active, able to carry on all pre disease activities without restriction (Karnofsky ) 1 Restricted in physical strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, for example, light housework or office work (Karnofsky 70 80) 2 Ambulatory and capable of all self care but unable to carry out any work activities. Up and about greater than or equal to 50% of waking hours (Karnofsky 50 60) 3 Capable of only limited self care, confined to bed or chair greater than or equal to 50% of waking hours (Karnofsky 30 40) 4 Completely disabled, cannot carry on any self care, totally confined to bed or chair (Karnofsky 10 20) Oken MM, Creech RH, et al. Toxicity and Response Criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: , Eastern Cooperative Oncology Group Robert Comis M.D., Group Chair Effective: May 2012 Required Update: February 2014 Annual Review: February 2013 Approved: Ferbuary 2013 p. 15
17 Systemic Therapy Summary 16 Appendix III Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 Publish Date: 18 May 2009 Grades Grade refers to the severity of the AE. The CTCAE displays grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age appropriate instrumental ADL*. Grade 3 Severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL**. Grade 4 Life threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. A semi colon indicates or within the description of the grade. A single dash ( ) indicates a grade is not available. Not all grades are appropriate for all AEs. Therefore, some AEs are listed with fewer than five options for grade selection. Grade 5: Grade 5 (Death) is not appropriate for some AEs and therefore is not an option Activities of Daily Living (ADL): * Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc. ** Self care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden. CTCAE document available at: Accessed 10 September 2010 Effective: May 2012 Required Update: February 2014 Annual Review: February 2013 Approved: Ferbuary 2013 p. 16
18 Systemic Therapy Summary 17 CancerCare Manitoba 675 McDermot Avenue Winnipeg, Manitoba, Canada R3E 0V9 CCMB STS: GENU Temsirolimus January 2009 Effective: January 2009 Approved: February 2013 CancerCare Manitoba, February All rights reserved. This material may be freely reproduced for educational and not for profit purposes. No reproduction by or for commercial organization, or for commercial purposes is allowed without written permission of CancerCare Manitoba. Effective: May 2012 Required Update: February 2014 Annual Review: February 2013 Approved: Ferbuary 2013 p. 17
First-Line Treatment of Advanced Renal Cell Carcinoma with Temsirolimus
Practice Guideline: Systemic Therapy Summary First-Line Treatment of Advanced Renal Cell Carcinoma with Temsirolimus (GENU Temsirolimus) Genitourinary Disease Site Group Effective: January 2009 Updated:
More informationFirst-Line Treatment of Advanced Renal Cell Carcinoma with Oral Sunitinib
Practice Guideline: Systemic Therapy Summary First-Line Treatment of Advanced Renal Cell Carcinoma with Oral Sunitinib (GENU Sunitinib (MRCC)) Genitourinary Disease Site Group Effective: February 2008
More informationFirst-Line Treatment of Locally Advanced or Metastatic Biliary Tract Carcinoma with Cisplatin and Gemcitabine
Practice Guideline: Systemic Therapy Summary First-Line Treatment of Locally Advanced or Metastatic Biliary Tract Carcinoma with Cisplatin and Gemcitabine (GAST- Cisplatin + Gemcitabine) Gastro-Intestinal
More informationFirst-Line Treatment of HER2/neu Positive Metastatic Breast Cancer with Trastuzumab. (BREAST Trastuzumab) Breast Disease Site Group
Practice Guideline: Systemic Therapy Summary First-Line Treatment of HER2/neu Positive Metastatic Breast Cancer with Trastuzumab (BREAST Trastuzumab) Breast Disease Site Group Effective: May 2009 Updated:
More informationGastro-Intestinal Disease Site Group. Effective: January 2013 Required Update: April 2016 Annual Review:
Practice Guideline: Systemic Therapy Summary First-Line Treatment of HER2/neu Positive Locally Advanced, Recurrent or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction with Trastuzumab
More informationGynecologic Oncology Disease Site Group. Effective: May 2010
Practice Guideline: Systemic Therapy Summary First- or Second-Line Treatment of Metastatic or Locally Advanced Uterine Leiomyosarcoma with Fixed-Dose Rate Gemcitabine and Docetaxel (GYNE Gemcitabine +
More informationArsenic Trioxide for Acute Promyelocytic Leukemia
Practice Guideline: Systemic Therapy Summary Arsenic Trioxide for Acute Promyelocytic Leukemia (LEUK Arsenic Trioxide) Leukemia Disease Site Group Effective: June 2014 Required Update: September 2016 Annual
More informationDose-Dense Paclitaxel Combined with Carboplatin for Advanced/Metastatic Ovarian Cancer (GYNE Paclitaxel + Carbo (dose-dense))
Practice Guideline: Systemic Therapy Summary Dose-Dense Paclitaxel Combined with Carboplatin for Advanced/Metastatic Ovarian Cancer (GYNE Paclitaxel + Carbo (dose-dense)) Gynecologic Oncology Disease Site
More informationNPAC(W)+PERT+TRAS Regimen
Regimen Monograph Regimen Name Drug Regimen Cycle Frequency Premedication and Supportive Measures Dose Modifications Adverse Effects Interactions Drug Administration and Special Precautions Recommended
More informationNPAC+PERT+TRAS Regimen
Regimen Monograph Regimen Name Drug Regimen Cycle Frequency Premedication and Supportive Measures Dose Modifications Adverse Effects Interactions Drug Administration and Special Precautions Recommended
More informationPREMEDICATIONS: Antiemetic protocol for highly emetogenic chemotherapy. May not need any antiemetic with
BCCA Protocol Summary for Palliative Therapy of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, or Anal Squamous Cell Carcinoma using
More informationBCCA Protocol Summary for Second line Treatment of Metastatic or Unresectable Pancreatic Adenocarcinoma Using Capecitabine
BCCA Protocol Summary for Second line Treatment of Metastatic or Unresectable Pancreatic Adenocarcinoma Using Capecitabine Protocol Code Tumour Group Contact Physician GIPAVCAP Gastrointestinal GI Systemic
More informationAC-DOCE Regimen. AC-DOCE+TRAS Regimen AC-DOCE AC-DOCE+TRAS. A - Regimen Name. Disease Site Breast. Adjuvant. Regimen Category. Evidence-Informed :
Regimen Monograph Regimen Name Drug Regimen Cycle Frequency Premedication and Supportive Measures Dose Modifications Adverse Effects Interactions Drug Administration and Special Precautions Recommended
More informationBCCA Protocol Summary for Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using Fluorouracil and Platinum
BCCA Protocol Summary for Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using Fluorouracil and Platinum Protocol Code: Tumour Group: Contact Physician: HNAVFUP Head and Neck
More informationBCCA Protocol Summary for Curative Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, Capecitabine and Radiation Therapy
BCCA Protocol Summary for Curative Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, and Radiation Therapy Protocol Code: Tumour Group: Contact Physician: GICART Gastrointestinal
More informationPACL(W)+RAMU Regimen PACL(W)+RAMU. A - Regimen Name. Gastrointestinal - Esophagus Gastrointestinal - Gastric / Stomach.
Regimen Monograph Regimen Name Drug Regimen Cycle Frequency Premedication and Supportive Measures Dose Modifications Adverse Effects Interactions Drug Administration and Special Precautions Recommended
More informationThe Use of Inhibitors of Angiogenesis in Patients with Inoperable Locally Advanced or Metastatic Renal Cell Cancer: Guideline Recommendations
Evidence-Based Series #3-8-4: Section 1 The Use of Inhibitors of Angiogenesis in Patients with Inoperable Locally Advanced or Metastatic Renal Cell Cancer: Guideline Recommendations S. Hotte, T. Waldron,
More informationCLINICAL POLICY Department: Medical Management Document Name: Inlyta Reference Number: NH.PHAR.100 Effective Date: 05/12
Page: 1 of 5 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationBreast Pathway Group Gemcitabine & Paclitaxel in Advanced Breast Cancer
Breast Pathway Group Gemcitabine & Paclitaxel in Advanced Breast Cancer Indication: Alternative palliative treatment for advanced breast cancer in patients where docetaxel monotherapy or docetaxel/capecitabine
More informationBCCA Protocol Summary for Therapy of Multiple Myeloma Using Pomalidomide with Dexamethasone
BCCA Protocol Summary for Therapy of Multiple Myeloma Using Pomalidomide with Dexamethasone Protocol Code UMYPOMDEX Tumour Group Contact Physician Contact Pharmacist Lymphoma, Leukemia/BMT Dr. Kevin Song
More informationBCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide and DOCEtaxel
BCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin Cyclophosphamide DOCEtaxel Protocol Code Tumour Group Contact Physician BRAJFECD Breast Dr. Stephen Chia ELIGIBILITY:
More informationBCCA Protocol Summary for Therapy of Metastatic Breast Cancer using Capecitabine
BCCA Protocol Summary for Therapy of Metastatic Breast Cancer using Capecitabine Protocol Code Tumour Group Contact Physician BRAVCAP Breast Dr. Susan Ellard ELIGIBILITY: First line treatment of metastatic
More informationBCCA Protocol Summary for Adjuvant Therapy of Colon Cancer using
BCCA Protocol Summary for Adjuvant Therapy of Colon Cancer using Capecitabine Protocol Code Tumour Group Contact Physician GIAJCAP Gastrointestinal GI Systemic Therapy ELIGIBILITY: Resected Stage III or
More informationBRAVTRAD. Protocol Code: Breast. Tumour Group: Dr. Susan Ellard. Contact Physician:
BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab (HERCEPTIN) and DOCEtaxel as First-Line Treatment for Advanced Breast Cancer Protocol Code: Tumour Group: Contact
More informationWARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,
Celgene Corporation 86 Morris Avenue Summit, New Jersey 07901 Tel 908-673-9000 Fax 908-673-9001 October 2012 NEW Indication Announcement for ABRAXANE for Injectable Suspension (paclitaxel protein-bound
More informationPaclitaxel Gastric Cancer
Systemic Anti Cancer Treatment Handbook Paclitaxel Gastric Cancer PROTOCOL REF: MPHAUGIPAC (Version No: 1.0) Approved for use in: Second line treatment of locally advanced and metastatic gastric / gastro-oesophageal
More informationBC Cancer Protocol Summary for Adjuvant Therapy of Colon Cancer using Fluorouracil Injection and Infusion and Leucovorin Infusion
BC Cancer Protocol Summary for Adjuvant Therapy of Colon Cancer using Fluorouracil Injection and Infusion and Leucovorin Infusion Protocol Code: Tumour Group: Contact Physician: GIAJFL Gastrointestinal
More informationPRODUCT INFORMATION 1 ABOUT THIS GUIDE DOSAGE FORM AND STRENGTH STORAGE AND HANDLING
DOSING GUIDE INDICATION ONIVYDE (irinotecan liposome injection) is indicated, in combination with fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic adenocarcinoma of
More informationCycle 1 PERTuzumab (day 1) and trastuzumab (day 2) loading doses: Drug Dose BC Cancer Administration Guideline
BC Cancer Protocol Summary for Palliative Therapy for Metastatic Breast Cancer Using PERTuzumab, Trastuzumab (HERCEPTIN), and PACLItaxel as First-Line Treatment for Advanced Breast Cancer Protocol Code:
More informationXALKORI (crizotinib) oral capsule
XALKORI (crizotinib) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationImmune-Mediated Adverse Events Management Handbook
Immune-Mediated Adverse Events Management Handbook Your guide to addressing the immune-mediated adverse events (imaes) associated with patients taking PD-L1 inhibition therapy Indications and Usage IMFINZI
More informationEXCLUSIONS: Suspected dihydropyrimidine dehydrogenase (DPD) deficiency (see Precautions)
BC Cancer Protocol Summary for Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Fluorouracil Injection and Infusion and Leucovorin Infusion Protocol Code: Tumour Group: Contact
More informationSunitinib (renal) ICD-10 codes Codes with a prefix C64
Sunitinib (renal) Indication First line treatment of patients with advanced and/or metastatic renal cell carcinoma who are suitable for immunotherapy and have an Eastern Cooperative Oncology Group (ECOG)
More informationTemsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features
Annals of Oncology 19: 1387 1392, 2008 doi:10.1093/annonc/mdn066 Published online 2 April 2008 Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma
More informationAntiemetic protocol for low-moderately emetogenic chemotherapy (see SCNAUSEA)
BC Cancer Protocol Summary for First Line Treatment of Locally Advanced Metastatic Pancreatic Cancer with Gemcitabine Protocol Code Tumour Group Contact Physician GIPGEMABR Gastrointestinal GI Systemic
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationBRAVTPCARB. Protocol Code: Breast. Tumour Group: Dr. Karen Gelmon. Contact Physician:
BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab (HERCEPTIN), PACLitaxel and CARBOplatin as First-Line Treatment for Advanced Breast Cancer Protocol Code: Tumour
More informationNCCP Chemotherapy Regimen
INDICATIONS FOR USE: Azacitidine i INDICATION ICD10 Regimen Code *Reimbursement Status Intermediate-1 and low risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System
More informationSubject: Cobimetinib (Cotellic ) Tablet
09-J2000-53 Original Effective Date: 03/15/16 Reviewed: 11/14/18 Revised: 12/15/18 Subject: Cobimetinib (Cotellic ) Tablet THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationTRANSPARENCY COMMITTEE OPINION. 27 January 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 January 2010 TORISEL 25 mg/ml, concentrate for solution and diluent for solution for infusion Box containing 1
More informationBCCA Protocol Summary for the Treatment of BRAF V600 Mutation- Positive Unresectable or Metastatic Melanoma Using dabrafenib and Trametinib
BCCA Protocol Summary for the Treatment of BRAF V600 Mutation- Positive Unresectable or Metastatic Melanoma Using dabrafenib and Protocol Code Tumour Group Contact Physician USMAVDT Skin and Melanoma Dr.
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Approved By: Provider Notice Date: CLINICAL MEDICAL POLICY Portrazza (Necitumumab) MP-021-MD-WV Medical Management Original Effective Date: 06/02/2016 Annual Approval Date:
More informationSCALES SCALES SCALES. Performance Scales WHAT SHOULD THE RAINBOW FISH DO WITH ALL OF THESE SCALES?? KPS FAST ECOG PPS NYHA MRI ALSFRS
SCALES SCALES SCALES WHAT SHOULD THE RAINBOW FISH DO WITH ALL OF THESE SCALES?? Karen L. Cross, MD, FAAHPM Performance Scales KPS FAST ECOG PPS NYHA MRI ALSFRS PPS = 30, 40, or 50 ECOG = 2, 3, or 4 NYHA
More informationBreast Pathway Group Everolimus in Advanced Breast Cancer
Breast Pathway Group Everolimus in Advanced Breast Cancer Indication: Hormone receptor positive, HER2 negative advanced breast cancer National Cancer Drug Fund criteria: ER+ve, HER2 ve metastatic breast
More informationCancer Treatment in the Elderly. Jeffrey A. Bubis, DO, FACOI, FACP Clay County, Baptist South, and Palatka
Cancer Treatment in the Elderly Jeffrey A. Bubis, DO, FACOI, FACP Clay County, Baptist South, and Palatka Patients 65 and older are the fastest growing segment of the US population By 2030, it will comprise
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More informationFDA Approves ABRAXANE for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
October 12, 2012 FDA Approves ABRAXANE for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Approval Based on Significantly Improved Overall Response Rates in all Patients Regardless of
More informationBCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide
BCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin Cyclophosphamide Protocol Code Tumour Group Contact Physician BRAJFEC Breast Dr. Susan Ellard ELIGIBILITY: Patients
More informationBC Cancer Protocol Summary for Therapy of Adjuvant Breast Cancer using Capecitabine
BC Cancer Protocol Summary for Therapy of Adjuvant Breast Cancer using Capecitabine Protocol Code Tumour Group Contact Physician BRAJCAP Breast Dr. Stephen Chia ELIGIBILITY: Adjuvant breast cancer therapy
More informationBCCA Protocol Summary for Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using PONAtinib
BCCA Protocol Summary for Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using PONAtinib Protocol Code Tumour Group Contact Physician ULKCMLP Leukemia Dr. Donna Forrest ELIGIBILITY:
More informationBCCA Protocol Summary for Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma using Capecitabine and Radiation Therapy
BCCA Protocol Summary for Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma using Capecitabine and Radiation Therapy Protocol Code: Tumour Group: Contact Physician: GIRCRT Gastrointestinal
More informationNCCP Chemotherapy Protocol. Nab-Paclitaxel (Abraxane ) Monotherapy 21 day cycle
Nab-Paclitaxel (Abraxane ) Monotherapy 21 day cycle INDICATIONS FOR USE: INDICATION Treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and
More informationNCCP Chemotherapy Regimen
INDICATIONS FOR USE: SUNitinib 50mg Therapy INDICATION ICD10 Regimen Code *Reimbursement Status Treatment of unresectable and/or metastatic malignant gastrointestinal C26 00325a CDS stromal tumour (GIST)
More informationNCCP Chemotherapy Protocol
Docetaxel Monotherapy 50mg/m 2 INDICATIONS FOR USE: INDICATION In combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer
More informationSAALT3W Sarcoma Dr. Meg Knowling. Protocol Code Tumour Group Contact Physician
BCCA Protocol Summary for Etoposide, Ifosfamide-Mesna (SAIME) Alternating with vincristine, DOXOrubicin and Cyclophosphamide (with or without Mesna)(SAVAC or SAVACM) with Filgrastim Support at a THREE
More informationNCCP Chemotherapy Regimen. Alectinib Monotherapy
INDICATIONS FOR USE: Alectinib INDICATION ICD10 Regimen Code *Reimbursement Indicator Treatment of adult patients with anaplastic lymphoma kinase (ALK)- positive advanced non-small cell lung cancer (NSCLC)
More informationCisplatin and Gemcitabine (bladder)
Cisplatin and Gemcitabine (bladder) Indication Palliative therapy for locally advanced or metastatic bladder cancer in patients with good renal function. Palliative therapy for urothelial transitional
More informationNab-PACLitaxel (Abraxane ) Monotherapy 21 day
Nab-PACLitaxel (Abraxane ) Monotherapy 21 day INDICATIONS FOR USE: INDICATION ICD10 Regimen Code *Reimbursement Status Treatment of metastatic breast cancer in adult patients who have failed first-line
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
into consideration the concerns of the patient. Upon reconsideration of the perc Initial Recommendation,the Committee discussed feedback from the patient advocacy group reporting concerns that the definition
More informationDRUG NAME: Temsirolimus
DRUG NAME: Temsirolimus SYNONYM(S): CCI-779 1 COMMON TRADE NAME(S): TORISEL CLASSIFICATION: miscellaneous Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM
More informationStudy No Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBRLAACDT. Protocol Code. Breast. Tumour Group. Dr. Karen Gelmon. Contact Physician
BCCA Protocol Summary for Treatment of Locally Advanced Breast Cancer using DOXOrubicin and Cyclophosphamide followed by DOCEtaxel and Trastuzumab (HERCEPTIN) Protocol Code Tumour Group Contact Physician
More informationCheckMate 025, as patients may derive a benefit, based on the opinion of the CGP and the mechanism of action of nivolumab.
CheckMate 025, as patients may derive a benefit, based on the opinion of the CGP and the mechanism of action of nivolumab. perc noted that patients with brain metastases were excluded from the CheckMate
More informationKidney Cancer. Version February 6, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines )
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Kidney Cancer Overall management of Kidney Cancer from diagnosis through recurrence is described in the full NCCN Guidelines for Kidney
More informationNCCP Chemotherapy Regimen
Modified Roswell Park (Fluorouracil 500mg/m 2 and Folinic Acid 50mg weekly x 6) Regimen INDICATIONS FOR USE: Regimen INDICATION ICD10 Code Treatment of metastatic colorectal cancer C18 00427a Adjuvant
More informationNCCP Chemotherapy Regimen. PAZOPanib Therapy
INDICATIONS FOR USE: PAZOPanib Therapy Regimen Code INDICATION ICD10 First line treatment of advanced Renal Cell Carcinoma (RCC) in adults and for C64 00445a patients who have received prior cytokine therapy
More informationComorbidities in Multiple Myeloma
Comorbidities in Multiple Myeloma Michel Delforge, MD, PhD University Hospital Leuven Leuven, Belgium COMy, Bangkok 12 may 2014 Comy Meeting, Bangkok, 12 may 2014 Disclosures Advisory board: Janssen,
More informationNCCP Chemotherapy Regimen. FLOT Therapy-14 day
INDICATIONS FOR USE: FLOT Therapy-14 Regimen Code 00344a *Reimbursement Indicator INDICATION ICD10 Treatment of locally advanced ( T2) and/or nodal positive (N+) C16 resectable gastric adenocarcinoma Treatment
More informationSAFETY CONSIDERATIONS WITH YONDELIS (trabectedin)
SAFETY CONSIDERATIONS WITH YONDELIS (trabectedin) Please see Important Safety Information on pages 14 and 15 and accompanying full Prescribing Information. YONDELIS (trabectedin) STUDY DESIGN INDICATION
More informationALUNBRIG (brigatinib) Dosing Guide
ALUNBRIG (brigatinib) Dosing Guide INDICATION ALUNBRIG (brigatinib) is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)
More informationNCCP Chemotherapy Regimen
QUASAR (Modified) Fluorouracil (370mg/m 2 ) and Folinic Acid (50mg) Weekly INDICATIONS FOR USE: Regimen INDICATION ICD10 Code Treatment of metastatic colorectal cancer C18 00428a Adjuvant treatment of
More informationThis is a controlled document and therefore must not be changed
AZACITIDINE NICE TA218 Treatment of adults not eligible for haematopoietic stem cell transplantation who have: Intermediate-2 and high-risk MDS according to the International Prognostic Scoring System
More informationNational Horizon Scanning Centre. Temsirolimus (Torisel) for mantle cell lymphoma - relapsed and/or refractory. January 2008
Temsirolimus (Torisel) for mantle cell lymphoma - relapsed and/or refractory January 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationWest of Scotland Cancer Network Chemotherapy Protocol
West of Scotland Cancer Network Chemotherapy Protocol DOCETAXEL/TRASTUZUMAB (BRWOS-005/1) Indication Docetaxel in combination with is indicated for the treatment of patients with HER2 overexpressing locally
More informationLung Pathway Group Carboplatin & PO Vinorelbine in Non-Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Carboplatin & PO Vinorelbine in Non-Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in
More informationBC Cancer Protocol Summary for Therapy of Acute Myeloid Leukemia Using azacitidine and SORAfenib
BC Cancer Protocol Summary for Therapy of Acute Myeloid Leukemia Using azacitidine and SORAfenib Protocol Code Tumour Group Contact Physician ULKAMLAS Leukemia/BMT Dr. Donna Hogge ELIGIBILITY: Acute myeloid
More informationBCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer Using Trastuzumab (HERCEPTIN) and Capecitabine
BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer Using Trastuzumab (HERCEPTIN) and Capecitabine Protocol Code Tumour Group Contact Physician UBRAVTCAP Breast Dr. Stephen Chia ELIGIBILITY:
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationCelgene Receives Positive CHMP Opinion for ABRAXANE in Combination with Gemcitabine as Treatment for Patients with Metastatic Pancreatic Cancer
November 22, 2013 Celgene Receives Positive CHMP Opinion for ABRAXANE in Combination with Gemcitabine as Treatment for Patients with Metastatic Pancreatic Cancer BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene
More informationLapatinib and Capecitabine Therapy
Lapatinib and Capecitabine Therapy This protocol should be read in conjunction with NCCP protocol 00216 Capecitabine Monotherapy. INDICATIONS FOR USE: INDICATION Treatment of adult patients with breast
More informationHorizon Scanning Technology Briefing. Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma
Horizon Scanning Technology Briefing National Horizon Scanning Centre Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma August 2006: Updated October 2006 This technology
More informationBC Cancer Protocol for Treatment of Platinum Resistant Epithelial Ovarian Cancer with Bevacizumab and PACLitaxel
BC Cancer Protocol for Treatment of Platinum Resistant Epithelial Ovarian Cancer with Bevacizumab and PACLitaxel Protocol Code Tumour Group Contact Physician UGOOVBEVP Gynecologic Oncology Dr. Anna Tinker
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma September 1, 2016
pan-canadian Oncology Drug Review Final Clinical Guidance Report Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma September 1, 2016 DISCLAIMER Not a Substitute for Professional Advice This report
More informationSpecial pediatric considerations are noted when applicable, otherwise adult provisions apply.
DRUG NAME: Lomustine SYNONYM(S): CCNU 1 COMMON TRADE NAME(S): CeeNU CLASSIFICATION: alkylating agent Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
of the clinical trial data for this outcome. Therefore, perc considered that the cost-effectiveness of cetuximab plus FOLFIRI would be at the higher end of the EGP s range of best estimates. Therefore,
More informationCABAZITAXEL Prostate Cancer
Systemic Anti-Cancer Treatment Protocol CABAZITAXEL Prostate Cancer PROCTOCOL REF: MPHACABAZ (Version No: 1.0) Approved for use in: Cabazitaxel in combination with prednisolone is a treatment option for
More informationStandard care plan for 1 st line palliative chemotherapy in advanced non small cell lung cancer References
CHEMOTHERAPY CARE PLAN Document Title: Document Type: Subject: Approved by: Currency: Carboplatin & Gemcitabine combination chemotherapy (Lung cancer) Clinical Guideline Standard Care Plan 2 Years Review
More informationScottish Medicines Consortium
Scottish Medicines Consortium cetuximab 2mg/ml intravenous infusion (Erbitux ) (279/06) MerckKGaA No 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationScottish Medicines Consortium
Scottish Medicines Consortium sorafenib 200mg tablets (Nexavar ) (No. 321/06) Bayer Plc 6 October 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises
More informationOVERALL CLINICAL BENEFIT
cetuximab plus FOLFIRI to convert unresectable liver metastatses to resectable, perc confirmed that neither the FIRE-3 study nor the CRYSTAL study were designed to assess resectability and, in the absence
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-5412862:2.0 Research & Development, L.L.C. Protocol No.: R115777-AML-301 Title of Study: A Randomized Study of Tipifarnib Versus Best Supportive Care
More informationMetastatic renal cancer (mrcc): Evidence-based treatment
Metastatic renal cancer (mrcc): Evidence-based treatment José M. Ruiz Morales, M.D. Hospital Médica Sur April 18th, 2018 4th ESO-ESMO Latin American Masterclass in Clinical Oncology Disclosures Consulting:
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationSpecialist Palliative Care Referral for Patients
Specialist Palliative Care Referral for Patients This guideline covers referrals for patients with progressive terminal illness, whether due to cancer or other disease. For many patients in the late stages
More informationULYRICE. Protocol Code. Lymphoma. Tumour Group. Dr. Laurie Sehn. Contact Physician
BCCA Protocol Summary for the Treatment of Relapsed or Refractory Advanced Stage Aggressive B-Cell Non-Hodgkin s Lymphoma with Ifosfamide, CARBOplatin, Etoposide and rituximab Protocol Code Tumour Group
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 November 2006 TAXOTERE 20 mg, concentrate and solvent for infusion in single-dose vials of 7 ml, individually packed
More informationATEZOLIZUMAB (TECENTRIQ ) in urothelial carcinoma
DRUG ADMINISTRATION SCHEDULE Day Drug Daily Dose Route Diluent Rate Day 1 Atezolizumab 1200 mg IV Infusion 250mL 0.9% Sodium Chloride Over 60 minutes* *The initial dose of atezolizumab must be administered
More informationNCCP Chemotherapy Regimen
INDICATIONS FOR USE: Capecitabine Monotherapy Regimen *Reimbursement INDICATION ICD10 Code Indicator Treatment of patients with locally advanced or metastatic breast cancer C50 00216a CDS Treatment of
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More information